ATRC Stock Performance, Insider Transaction and News

ATRC - AtriCure, Inc.

Market Cap	2.69B	P/E	-	EPS this Y	-18.20%	Ern Qtrly Grth	-
Income	-37.23M	Forward P/E	-65.40	EPS next Y	19.20%	50D Avg Chg	13.00%
Sales	414.6M	PEG	-1.45	EPS past 5Y	-	200D Avg Chg	28.00%
Dividend	N/A	Price/Book	5.83	EPS next 5Y	20.00%	52W High Chg	-5.00%
Recommedations	1.70	Quick Ratio	2.63	Shares Outstanding	48.38M	52W Low Chg	75.00%
Insider Own	3.20%	ROA	-3.86%	Shares Float	46.73M	Beta	1.41
Inst Own	105.90%	ROE	-8.17%	Shares Shorted/Prior	2.98M/3.25M	Price	56.90
Gross Margin	75.26%	Profit Margin	-8.98%	Avg. Volume	291,016	Target Price	49.00
Oper. Margin	-10.03%	Earnings Date	Jul 23	Volume	376,693	Change	1.16%

Healthcare | Medical Instruments & Supplies | United States

About AtriCure, Inc.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure, Inc. News

05/15/24	AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
05/04/24	AtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price Target
05/03/24	The past three years for AtriCure (NASDAQ:ATRC) investors has not been profitable
05/03/24	AtriCure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
05/02/24	AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript
05/02/24	AtriCure Inc (ATRC) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
05/01/24	Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics
05/01/24	AtriCure Inc (ATRC) Surpasses Revenue Estimates in Q1 2024 Despite Wider Losses
05/01/24	AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
05/01/24	AtriCure Reports First Quarter 2024 Financial Results
04/30/24	AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference
08:45 AM	AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
04/18/24	AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
04/10/24	AtriCure to Announce First Quarter 2024 Financial Results
03/26/24	AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03/22/24	AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug
03/07/24	Chief Legal Officer Karl Dahlquist Sells 8,231 Shares of AtriCure Inc (ATRC)
02/28/24	AtriCure (ATRC) Fell on Competitor Action
02/17/24	AtriCure Full Year 2023 Earnings: EPS Beats Expectations
02/16/24	AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call Transcript

ATRC Chatroom

insiderbuyingselling Posted - 2 weeks ago

$ATRC new insider selling: 1500 shares. http://insiderbuyingselling.com/?t=ATRC

IN0V8 Posted - 2 weeks ago

$ATRC BTIG cuts target price to $58 from $65 Canaccord Genuity cuts target price to $49 from $57 JP Morgan cuts target price to $34 from $42 Needham cuts target price to $40 from $46 Stifel cuts target price to $30 from $42

Stocksrunner Posted - 2 weeks ago

📉 Top Losers $FSLY Tumbling on a weak forecast, optimism fades. $FRSH plunges over 25% as CEO departure shakes confidence. $ATRC misses estimates, with revenue up but EPS down. $RELY struggles as earnings call fails to impress. $WEAV feels the sting of disappointing Q1 results. It's a rough day for these stocks, with gloom dominating the market sentiment. 😔 https://stocksrunner.com/trending

epsguid Posted - 2 weeks ago

$ATRC reported a loss of $0.25, consensus was ($0.21) via @eWhispers #epsmiss http://eps.sh/d/atrc

Estimize Posted - 2 weeks ago

$ATRC misses the Estimize EPS Consensus by 3c and beats the Estimize Revenue Consensus by $1.44M. Reports FQ1 earnings of -25c EPS and ... http://www.estimize.com/atrc/fq1-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

Stock_Titan Posted - 2 weeks ago

$ATRC AtriCure Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/ATRC/atri-cure-reports-first-quarter-2024-financial-cap635m3hrot.html

Estimize Posted - 2 weeks ago

$ATRC reports after the close, Estimize Consensus +0.01 EPS and +0.55M Revs compared to WS http://www.estimize.com/atrc/fq1-2024?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

Stock_Titan Posted - 04/30/24

$ATRC AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference https://www.stocktitan.net/news/ATRC/atri-cure-to-participate-in-the-2024-bank-of-america-securities-kumzsa1y092w.html

briefingcom Posted - 04/23/24

$ATRC (+3.8%) upgraded to Outperform from Perform at Oppenheimer; tgt $32 https://www.briefing.com/calendars/updown?Filter=Upgrades

Stock_Titan Posted - 1 month ago

$ATRC AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management https://www.stocktitan.net/news/ATRC/atri-cure-announces-launch-of-the-cryo-sphere-r-probe-for-post-di71xvdp03oi.html

Stock_Titan Posted - 1 month ago

$ATRC AtriCure to Announce First Quarter 2024 Financial Results https://www.stocktitan.net/news/ATRC/atri-cure-to-announce-first-quarter-2024-financial-d7fuh6h7jh10.html

Thestocktraderhubzee Posted - 1 month ago

WATCHLIST APR 10 2024.. $AUTL Truist Securities Maintains Buy on Autolus Therapeutics, Raises Price Target to $11 $ATRC Needham Reiterates Buy on AtriCure, Maintains $46 Price Target $UDR Truist Securities Maintains Buy on UDR, Lowers Price Target to $42 $ESS Truist Securities Maintains Hold on Essex Property Trust, Lowers Price Target to $255 $EQR Truist Securities Maintains Buy on Equity Residential, Lowers Price Target to $67

insiderbuyingselling Posted - 1 month ago

$ATRC new insider selling: 1500 shares. http://insiderbuyingselling.com/?t=ATRC

Stock_Titan Posted - 03/26/24

$ATRC AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/ATRC/atri-cure-to-participate-in-the-23rd-annual-needham-virtual-cjtzoixjpz6q.html

Office21 Posted - 03/20/24

$ATRC brutal

insiderbuyingselling Posted - 03/20/24

$ATRC new insider selling: 1885 shares. http://insiderbuyingselling.com/?t=ATRC

drknmstr01 Posted - 2 months ago

$ATRC Starting DD

insiderbuyingselling Posted - 2 months ago

$ATRC new insider selling: 1500 shares. http://insiderbuyingselling.com/?t=ATRC

insiderbuyingselling Posted - 2 months ago

$ATRC new insider selling: 8231 shares. http://insiderbuyingselling.com/?t=ATRC

TickerDD_com Posted - 02/21/24

From 2/20/2024, looking back across 22 Month-Ends for ATRC, Percentage Change of Average Monthly Price had Equal (50%) while Percentage Change of Average Monthly Volume had All Positives (100%) $ATRC #ATRC #ATRCStock #TickerDD #ATRCPrice https://www.youtube.com/watch?v=njYOQeHFiTQ

Fullratio Posted - 02/20/24

$ATRC revenue is up by 21% year-on-year and by 4.9% since the previous quarter: https://fullratio.com/stocks/nasdaq-atrc/atricure

Fullratio Posted - 3 months ago

$ATRC gross profit rose by 22% YoY and by 5% QoQ: https://fullratio.com/stocks/nasdaq-atrc/atricure

swingingtech Posted - 3 months ago

$TOST $COIN $ATRC $WEST https://wallstreetwaves.com/coinbase-to-rally-around-45-here-are-10-top-analyst-forecasts-for-friday/

Office21 Posted - 3 months ago

$ATRC let’s see this thing pop tomorrow. Long-term hold

Estimize Posted - 3 months ago

$ATRC beats the Estimize EPS Consensus by 1c and the Estimize Revenue Consensus by $0.30M. Reports FQ4 earnings of -21c EPS and $106.54... http://www.estimize.com/atrc/fq4-2023?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

epsguid Posted - 3 months ago

$ATRC reported a loss of $0.21, consensus was ($0.22) via @eWhispers #epsbeat http://eps.sh/d/atrc

DonCorleone77 Posted - 3 months ago

$ATRC AtriCure reports Q4 EPS (21c), consensus (23c) Reports Q4 revenue $106.5M, consensus $103.7M. "Our 2023 results showcase the broad-based expansion of our many growth drivers, balanced by disciplined investments as we make progress towards sustained profitability," said Michael Carrel, President and Chief Executive Officer at AtriCure. "We begin 2024 with strong momentum throughout our business and an unwavering focus on advancing innovation, clinical science and therapy awareness as we establish new standards of care for patients globally."

Stock_Titan Posted - 3 months ago

$ATRC AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results https://www.stocktitan.net/news/ATRC/atri-cure-reports-fourth-quarter-2023-and-full-year-2023-financial-butfgdjpfsk5.html

Estimize Posted - 3 months ago

$ATRC reports after the close, Estimize Consensus +0.01 EPS and +2.57M Revs compared to WS http://www.estimize.com/atrc/fq4-2023?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

VirmoMopire Posted - 01/30/24

$ATRC Just spotted some interesting activity on this one. 🧐

Analyst Ratings

Canaccord Genuity	Buy	May 2, 24
JP Morgan	Overweight	May 2, 24
Needham	Buy	May 2, 24
Oppenheimer	Outperform	Apr 23, 24
Needham	Buy	Apr 10, 24
UBS	Buy	Feb 16, 24
Stifel	Buy	Feb 16, 24
Needham	Buy	Feb 16, 24
Needham	Buy	Jan 4, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Dahlquist Karl S.	Chief Legal Officer Chief Legal Officer	Nov 01	Sell	34.43	1,248	42,969	30,789	11/03/23
Dahlquist Karl S.	Chief Legal Officer Chief Legal Officer	Jul 26	Sell	57.09	3,417	195,077	32,037	07/28/23
Prange Karen	Director Director	Jun 08	Sell	47.89	713	34,146	16,140	06/12/23
Dahlquist Karl S.	Chief Legal Officer Chief Legal Officer	Jun 06	Sell	47.03	1,422	66,877	34,897	06/07/23
Yuen Maggie	Director Director	May 26	Sell	47.04	4,313	202,884	4,682	05/30/23
Collar Mark A	Director Director	Mar 13	Option	9.30	10,000	93,000	100,871	03/15/23
WHITE ROBERT S.	Director Director	Aug 31	Option	8.48	15,000	127,200	55,799	09/02/22
Austin Tonya	Chief Human Resource.. Chief Human Resources Officer	May 13	Sell	42.69	3,203	136,736	17,621	05/17/22
Austin Tonya	Chief Human Resource.. Chief Human Resources Officer	Apr 08	Sell	61.59	282	17,368	20,824	04/12/22
Collar Mark A	Director Director	Mar 16	Option	8.40	10,000	84,000	87,307	03/18/22
WHITE ROBERT S.	Director Director	Mar 03	Option	8.48	15,000	127,200	37,235	03/07/22
Austin Tonya	Chief Human Resource.. Chief Human Resources Officer	Mar 04	Sell	67.66	1,409	95,333	21,106	03/07/22
Austin Tonya	Chief Human Resource.. Chief Human Resources Officer	Mar 02	Sell	69.86	4,885	341,266	22,515	03/04/22
Austin Tonya	Chief Human Resource.. Chief Human Resources Officer	Feb 11	Sell	67.97	2,490	169,245	20,340	02/15/22
Austin Tonya	Chief Human Resource.. Chief Human Resources Officer	Jan 14	Sell	66.11	2,719	179,753	22,830	01/18/22
WEHRWEIN SVEN	Director Director	May 05	Option	19.95	5,000	99,750	17,686	05/05/21
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Feb 04	Option	21.04	25,000	526,000	529,795	02/04/21
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Feb 04	Sell	60	25,000	1,500,000	504,795	02/04/21
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Jan 13	Option	21.04	25,000	526,000	529,795	01/13/21
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Jan 13	Sell	59	25,000	1,475,000	504,795	01/13/21
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Dec 28	Option	21.04	25,000	526,000	529,457	12/28/20
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Dec 28	Sell	58	25,000	1,450,000	504,504	12/28/20
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Dec 23	Option	21.04	74,751	1,572,761	529,504	12/23/20
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Dec 23	Sell	56	74,751	4,186,056	504,504	12/23/20
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Dec 21	Option	13.48	125,249	1,688,357	554,753	12/21/20
CARREL MICHAEL H	President, CEO, & Di.. President, CEO, & Director	Dec 21	Sell	51.63	125,249	6,466,606	504,504	12/21/20